Ulocuplumab inhibits the binding of CXCR4 to CXCL12, and has shown both in vitro as well as in vivo anti-tumor in a WM tumor xenograft model engrafted with CXCR4WHIM mutated tumor cells [96]. Here, CXCR4 is linked to neoplasm.